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A total of 49 unique clinical isolates of multidrug-resistant (MDR) Acinetobacter baumannii identified at a
tertiary medical center in Pittsburgh, Pennsylvania, between August 2006 and September 2007 were studied for
the genetic basis of their MDR phenotype. Approximately half of all A. baumannii clinical isolates identified
during this period qualified as MDR, defined by nonsusceptibility to three or more of the antimicrobials
routinely tested in the clinical microbiology laboratory. Among the MDR isolates, 18.4% were resistant to
imipenem. The frequencies of resistance to amikacin and ciprofloxacin were high at 36.7% and 95.9%,
respectively. None of the isolates was resistant to colistin or tigecycline. The presence of the carbapenemase
gene blaOXA-23 and the 16S rRNA methylase gene armA predicted high-level resistance to imipenem and
amikacin, respectively. blaOXA-23 was preceded by insertion sequence ISAba1, which likely provided a potent
promoter activity for the expression of the carbapenemase gene. The structure of the transposon defined by
ISAba1 differed from those reported in Europe, suggesting that ISAba1-mediated acquisition of blaOXA-23 may
occur as an independent event. Typical substitutions in the quinolone resistance-determining regions of the
gyrA and parC genes were observed in the ciprofloxacin-resistant isolates. Plasmid-mediated quinolone resis-
tance genes, including the qnr genes, were not identified. Fifty-nine percent of the MDR isolates belonged to a
single clonal group over the course of the study period, as demonstrated by pulsed-field gel electrophoresis.
Acinetobacter baumannii is a gram-negative, non-lactose-
fermenting organism that is increasingly recognized as a
major pathogen causing nosocomial infections including
bacteremia and ventilator-associated pneumonia, particu-
larly in patients admitted to intensive care units (23, 25).
The organism is characterized by its tendency to acquire
resistance to multiple classes of antimicrobials (3). Of note,
increasing resistance to carbapenems has been observed
worldwide in the past decade, frequently mediated by pro-
duction of Ambler’s class D -lactamases, which possess
carbapenemase activity (26). Several outbreaks caused by
multidrug-resistant (MDR) A. baumannii have been re-
ported from the United States (21, 22, 28). Additionally,
infections due to MDR A. baumannii have been observed in
military personnel returning from Iraq and Afghanistan (18,
29). The Infectious Diseases Society of America recently identi-
fiedA. baumannii as one of the six particularly problematic patho-
gens in terms of antimicrobial availability issues arising from
resistance (32).
The emergence of A. baumannii clinical isolates with resis-
tance to multiple classes of antimicrobials, including carbap-
enems, aminoglycosides, and fluoroquinolones, was observed
at our medical center in the latter half of 2006. For these
patients, therapeutic options were limited to salvage agents
such as colistin and tigecycline. In the present study, we con-
ducted a detailed investigation of the molecular epidemiology
and genetic basis of multidrug resistance among A. baumannii
clinical isolates identified at our medical center over a 1-year
period, with a focus on the mechanisms of carbapenem, amino-
glycoside, and fluoroquinolone resistance.
MATERIALS AND METHODS
Clinical isolates and definition of MDR. A. baumannii isolates recovered from
patient specimens at the University of Pittsburgh Medical Center (UPMC)
Presbyterian Campus between August 2006 and September 2007 were included
in this study. A. baumannii was identified in the clinical microbiology laboratory
by using the Gram-Negative Identification Panel (Microscan, Dade Behring Inc.,
Sacramento, CA). For automated identification in the electronic medical
records, MDR was defined as nonsusceptibility to three or more of the antimi-
crobials that are routinely tested in the clinical laboratory and to which A.
baumannii would have been expected to be susceptible. These included ampi-
cillin-sulbactam, piperacillin-tazobactam, cefepime, ciprofloxacin, trimethoprim-
sulfamethoxazole, a carbapenem (imipenem or meropenem), and an aminogly-
coside (amikacin, tobramycin, or gentamicin). As a result, 65 MDR isolates from
different patients were identified from this period. Forty-nine of the 65 isolates
were available for further analysis in the research laboratory. All the study
isolates were aliquoted and stored at 80°C until further use.
Susceptibility testing. The susceptibilities of the isolates to ampicillin-sulbac-
tam, ceftazidime, cefepime, meropenem, tobramycin, gentamicin, ciprofloxacin,
and tetracycline were tested using the standard disk diffusion method on Muel-
ler-Hinton (MH) agar plates (BD Microbiology Systems, Sparks, MD) and using
the breakpoints defined by the Clinical and Laboratory Standards Institute
(CLSI) (5). MICs of imipenem, amikacin, colistin, and tigecycline were deter-
mined by use of Etest strips (AB Biodisk, Solna, Sweden). They were also
interpreted according to the CLSI breakpoints, except for tigecycline, for which
the breakpoints endorsed by the British Society of Antimicrobial Chemotherapy
(BSAC) (MICs, 1 g/ml for susceptibility and 2 g/ml for resistance) were
used. BSAC is the only organization that has defined tigecycline breakpoints for
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A. baumannii. For non-imipenem-susceptible isolates, a phenotypic screening
test for metallo--lactamase production using sodium mercaptoacetic acid disks
was also conducted (2).
PFGE. For pulsed-field gel electrophoresis (PFGE), the genomic DNA was
digested with ApaI (New England Biolabs, Beverly, MA). The resultant frag-
ments were then separated by PFGE using a temperature-controlled CHEF DR
III system (Bio-Rad, Hercules, CA) as described previously (31). For PFGE
pattern analysis, Bionumerics software, version 4.0 (Applied Maths, Sint-Mar-
tens-Latem, Belgium), with the unweighted-pair group method using average
linkages and the Dice setting for clustering analysis was applied. The genetic
relatedness of isolates was determined by the criteria of Tenover et al. (33).
PCR analyses for detection of resistance genes. PCR analyses were performed
for detection of various resistance genes in all isolates. A loopful of bacteria was
taken from each fresh overnight culture on MH agar plates (BD Microbiology
Systems), suspended in 1 ml of sterile water, and boiled for 10 min. After
centrifugation, the supernatant was used as the template. Amplification was
performed using a 9700 GeneAmp thermocycler (Applied Biosystems, Foster
City, CA). The genes investigated included the carbapenemase genes blaOXA-23,
blaOXA-40, blaOXA-51, and blaOXA-58; the cephalosporinase gene blaADC; poten-
tial extended-spectrum -lactamase (ESBL) genes blaTEM, blaSHV, and
blaCTX-M; the 16S rRNA methylase gene armA; the aac(6)-Ib, aac(6)-Iad, and
aph(3)-VIa genes, encoding amikacin-modifying enzymes; and the plasmid-me-
diated quinolone resistance genes qnrA, qnrB, and qnrS. Select PCR products
were sequenced by use of an ABI 3100 instrument (Applied Biosystems). For
genes with negative results in PCRs in which no positive control was used
[blaOXA-40, blaOXA-58, and aac(6')-Iad], PCR amplifications were repeated at
least twice. A negative control was run with every PCR. The quinolone resis-
tance-determining regions (QRDRs) of the gyrA and parC genes of 13 isolates (1
representative isolate for each of the 10 pulsotypes identified in this study and 3
ciprofloxacin-susceptible control isolates from outside the study) were also am-
plified by PCR and subjected to sequencing. The primers used for the PCR
analyses are listed in Table 1.
Transfer of blaOXA-23. A. baumannii HE130 (a clinical strain susceptible to
carbapenems) and Escherichia coli DH10B were used as the recipients for trans-
formation experiments. AB017 and AB026, two blaOXA-23-positive isolates of
pulsotype A, were used as the donor strains. The competent cells of the recipient
strains were prepared and transformed by electroporation with plasmid DNA
extracted from the donor strains by the standard alkaline lysis method. The
transformants were selected on Luria-Bertani (LB) agar plates containing 2
g/ml of meropenem.
Cloning and sequencing of blaOXA-23. It has been demonstrated that OXA-23
confers high-level carbapenem resistance on A. baumannii when it is expressed
under the control of a potent promoter provided by insertion sequence ISAba1
(7, 16). To examine if this is the case for our isolates, the genetic environment of
blaOXA-23 was investigated. Genomic DNA of A. baumannii AB017 was digested
with XbaI and ligated with pBC-SK() (Stratagene, La Jolla, CA). Escherichia
coli DH10B was then transformed with the ligated products by electroporation.
Transformants that possessed recombinant plasmids carrying blaOXA-23 were
selected on LB agar plates containing chloramphenicol (25 g/ml) and ampicillin
(50 g/ml). The DNA insert obtained was sequenced on both strands using
custom sequencing primers.
Nucleotide sequence accession numbers. The nucleotide sequences reported
in this paper have been submitted to the GenBank/EMBL/DDBJ database under
accession no. EU594641.
TABLE 1. Primers used for amplification of resistance genes
Primers Sequences (5 to 3)a Target gene(s) Reference
OXA Set A FOR ATGAAAAAATTTATACTTCC blaOXA-24, blaOXA-25, blaOXA-26,
blaOXA-33, blaOXA-40, blaOXA-72
18
OXA Set A REV TTAAATGATTCCAAGATTTTC
OXA Set C FOR ACAGAARTATTTAAGTGGG blaOXA-51, blaOXA-58, blaOXA-64,
blaOXA-69, blaOXA-70, blaOXA-71,
blaOXA-75, blaOXA-78
18
OXA Set C REV GGTCTACAKCCMWTCCCCA
OXA 23 FOR GATGTGTCATAGTATTCGTCG blaOXA-23, blaOXA-27, blaOXA-49 1
OXA 23 REV TCACAACAACTAAAAGCACTG
OXA 58 5 ATGAAATTATTAAAAATATTGAGTTTAG blaOXA-58, blaOXA-96 18
OXA58 3 TTATAAATAATGAAAAACACCCAAC
ADC-7 FOR ATGCGATTTAAAAAAATTTCTTGT blaADC-1, blaADC-2, blaADC-3, blaADC4,
blaADC-5, blaADC-6, blaADC-7
18
ADC-7 REV TTATTTCTTTATTGCATTCAG
SHV S1 ATTTGTCGCTTCTTTACTCGC blaSHV 37
SHV S2 TTTATGGCGTTACCTTTGACC
TEM1 ATGAGTATTCAACATTTCCGTG blaTEM 11
TEM4 TTACCAATGCTTAATCAGTGAG
CTX-M/F TTTGCGATGTGCAGTACCAGTAA blaCTX-M 10
CTX-M/R CGATATCGTTGGTGGTGCCATA
CTXM 2 FOR AAATGTGCTGCTCCTTTCGTGAGC blaCTX-M-2 This study
CTXM 2 REV AGGGTTCGTTGCAAGACAAGACTG
ArmAf TGCATCAAATATGGGGGTCT armA This study
ArmAr GGATTGAAGCCACAACCAAA
aac(6)-1b f TTGCGATGCTCTATGAGTGGCTA aac(6)-Ib 24
aac(6)-1b r CTCGAATGCCTGGCGTGTTT
ABA-F TTTGGCTATGATCCTATG aac(6)-Iad 9
ABA-R CATGTCGAACAAGTACGC
APH F ATACAGAGACCACCATACAGT aph(3)-VI 36
APH R GGACAATCAATAATAGCAAT
gyrA-1 AAATCTGCCCGTGTCGTTGGT gyrA 18
gyrA-2 GCCATACCTACGGCGATACC
parC-1 AAACCTGTTCAGCGCCGCATT parC 18
parC-2 AAAGTTGTCTTGCCATTCACT
qnrA f ATTTCTCACGCCAGGATTTG qnrA 28a
qnrA r GATCGGCAAAGGTTAGGTCA
qnrB f GATCGTGAAAGCCAGAAAGG qnrB 28a
qnrB r ACGATGCCTGGTAGTTGTCC
qnrS f ACGACATTCGTCAACTGCAA qnrS 28a
qnrS r TAAATTGGCACCCTGTAGGC
a M stands for A or T; R stands for A or G; W stands for A or T; K stands for G or T.
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RESULTS
Antimicrobial susceptibility of MDR A. baumannii. A total
of 142 unique A. baumannii isolates were identified at the
clinical microbiology laboratory at UPMC during the study
period. Of those, 65 isolates (45.8%) met the MDR criteria
used in the present study. Among the 49 MDR isolates that
were available for the study, rates of full resistance were as
follows: 95.9% for ciprofloxacin, 87.8% for ceftazidime, 79.6%
for cefepime, 40.8% for ampicillin-sulbactam, 18.4% for imi-
penem, 22.4% for meropenem, 36.7% for amikacin, 61.2% for
tobramycin, 77.6% for gentamicin, and 79.6% for tetracycline.
Overall, 8 out of the 49 isolates (16.3%) were resistant to six
classes of antibiotics tested (ampicillin-sulbactam, ciprofloxa-
cin, a cephalosporin, a carbapenem, tetracycline, and an amino-
glycoside). None of the isolates was resistant to colistin or
tigecycline. However, 55.1% showed tigecycline MICs between
1.5 and 2 g/ml, which are interpreted as intermediate accord-
ing to the BSAC breakpoints.
None of the non-imipenem-susceptible isolates gave a pos-
itive result with the phenotypic screening test for metallo--
lactamase production.
Molecular typing and clonal detection through PFGE. A
total of 10 pulsotypes that comprised genetically indistinguish-
able or closely related isolates were observed by PFGE. Pul-
sotype A was predominant, comprising 29 isolates identified at
different time points during the study period. Pulsotypes B, C,
and D were possibly related to pulsotype A. The other six
pulsotypes (E through J) were all different from each other as
well as from pulsotype A (Table 2; Fig. 1).
-Lactamase genes. The carbapenemase gene blaOXA-23 was
identified in all eight isolates for which imipenem MICs were
32 g/ml. In contrast, none of the isolates without blaOXA-23
had imipenem MICs of 32 g/ml (Tables 2 and 3). blaOXA-40
and blaOXA-58, the other frequently reported carbapenemase
genes in A. baumannii, were not detected in any of the isolates.
A blaOXA-51-like gene was identified in most isolates. OXA-
51-like oxacillinases constitute a group of -lactamases with
low-level catalytic efficiency for carbapenems (15). blaADC
genes, a group of cephalosporinase genes commonly found in
A. baumannii and related species (17), were detected in 81.6%
of the isolates. Only one isolate was susceptible to both cefta-
zidime and cefepime. Therefore, it was not possible to corre-
late cephalosporin resistance with the presence of blaADC.
In the investigation of ESBL genes, five isolates were found
to encode blaCTX-M, which was identified as blaCTX-M-2, upon
the sequencing of the entire structural gene (Table 2). These
isolates were all resistant to cefepime but not necessarily to cefta-
zidime or ampicillin-sulbactam. blaTEM was detected in 36 iso-
lates. Sequencing of select amplicons revealed that they encoded
TEM-1. blaSHV was not identified in any of the isolates.
TABLE 2. PCR results based on pulsotypes
Pulsotype
Total
no. of
strains
No. (%) of strains positive for the indicated:
-Lactamase gene Amikacin resistance gene
blaOXA-23 blaOXA-40 blaOXA-51 blaOXA-58 blaADC blaCTX-M-2 blaTEM blaSHV armA aph(3)-VIa aac(6)-Ib aac(6)-Iad
A 29 7 0 29 0 29 2 27 0 16 2 9 0
B 3 0 0 3 0 3 0 3 0 0 0 0 0
C 4 0 0 4 0 4 0 3 0 0 0 0 0
D 7 0 0 7 0 0 3 2 0 0 0 6 0
E 1 0 0 1 0 1 0 1 0 1 0 0 0
F 1 0 0 1 0 0 0 0 0 0 0 1 0
G 1 0 0 1 0 1 0 0 0 0 0 0 0
H 1 1 0 1 0 1 0 0 0 0 1 0 0
I 1 0 0 1 0 1 0 1 0 0 0 0 0
J 1 0 0 0 0 0 0 0 0 0 0 0 0
Total 49 8 (16.3) 0 (0) 48 (97.9) 0 (0) 40 (81.6) 5 (10.2) 36 (73.5) 0 (0) 17 (34.7) 3 (6.1) 16 (32.6) 0 (0)
FIG. 1. PFGE patterns of all pulsotypes identified in the study.
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Aminoglycoside resistance genes. Eighteen isolates were re-
sistant to amikacin. Among these, 17 were positive for armA, a
16S rRNA methylase gene (Table 2). All of the armA-positive
isolates had amikacin MICs of 256 g/ml (Table 4). The only
amikacin-resistant, armA-negative isolate had an amikacin
MIC of 128 g/ml. This isolate did not yield positive PCR
results for any of the three amikacin-modifying enzyme genes
investigated. aac(6)-Ib, an aminoglycoside acetyltransferase
gene, was present in 16 isolates. The deduced amino acid
sequences of select amplicons were consistent with AAC(6)-
Ib, but not with AAC(6)-Ib-cr, which has been implicated in
low-level resistance to fluoroquinolones. MICs of amikacin for
aac(6)-Ib-positive isolates ranged from 2 g/ml to 12 g/ml,
except for eight isolates that were armA positive as well. Three
isolates were positive for aph(3)-VIa, an aminoglycoside phos-
photransferase gene. Two of them were also armA positive.
The only aph(3)-VIa-positive, armA-negative isolate had an
amikacin MIC of 12 g/ml. None of the study isolates was
positive for aac(6)-Iad, the other aminoglycoside acetyltrans-
ferase gene implicated in amikacin resistance in A. baumannii.
QRDRs and resistance genes. The sequencing results for the
QRDRs of gyrA and parC, encoding DNA gyrase and DNA
topoisomerase IV, respectively, revealed the presence of S83L
and S80L substitutions in the respective enzymes for all eight
ciprofloxacin-resistant isolates sequenced. The QRDRs of the
two ciprofloxacin-intermediate isolates in the study and of the
three susceptible control isolates did not possess substitutions
implicated in fluoroquinolone resistance in the amino acid
sequence of either gene. In addition, the V101I substitution in
gyrA was observed in all of the susceptible, intermediate, and
resistant isolates; this likely represented a polymorphism that
did not affect susceptibility to fluoroquinolones.
None of the isolates gave positive PCR results for the plas-
mid-mediated quinolone resistance gene qnrA, qnrB, or qnrS.
Transfer of blaOXA-23. Both AB017 and AB026 yielded
blaOXA-23-positive transformants with A. baumannii HE130 as
the recipient. Imipenem and meropenem MICs were 4 to 8
g/ml and 6 to 12 g/ml for the transformants compared with
0.5 g/ml and 0.125 g/ml for the recipient, respectively. No
transformants could be obtained with E. coli DH10B as the
recipient.
Genetic environment of blaOXA-23. A cloning experiment
yielded a recombinant plasmid with a 4.0-kb insert carrying
blaOXA-23. A schematic representation of its genetic environ-
ment is given in Fig. 2. As has been reported earlier for strains
from Europe and East Asia, blaOXA-23 was preceded by inser-
tion sequence ISAba1, encoding a transposase in the opposite
orientation. Promoter sequences consisting of the 35 se-
quence (TTAGAA) and the 10 sequence (TTATTT), known
to be responsible for the overexpression of -lactamase genes
located downstream of them (7, 16), were identified between
87 and 60 bp upstream of blaOXA-23. However, the left inverted
repeat of ISAba1 (i.e., the 5 end of ISAba1) was located closer
to the 5 end of blaOXA-23 due to the presence of a 7-bp
deletion compared with the corresponding sequence that was
initially characterized in Tn2006 from France (7). This partic-
ular deletion is also observed in sequences that have been
submitted from several other countries (nucleotide accession
no. AJ132105, EF120622, and EF016357). Furthermore, un-
like Tn2006, the transposon identified in this study, tentatively
designated Tn2008, was not part of a composite transposon.
The sequences flanking Tn2008 were distinct from those flank-
ing Tn2006. An open reading frame with moderate identity to
a putative DNA binding protein described in several A. bau-
mannii genome sequences was identified downstream of
Tn2008 (Fig. 2).
DISCUSSION
MDR A. baumannii has emerged as a substantial clinical
problem worldwide (23, 25, 26). This trend has paralleled the
overall increase in the prevalence of Acinetobacter spp., includ-
ing A. baumannii, as nosocomial pathogens. For example, data
from the National Nosocomial Infections Surveillance System
indicate that the proportion of Acinetobacter spp. associated
with pneumonia in intensive-care units increased from 4% in
1986 to 7% in 2003 in the United States (13). We recently
reported the emergence of two MDR A. baumannii isolates
that were highly resistant to both carbapenems and aminogly-
cosides due to production of both the OXA-23 carbapenemase
and the ArmA 16S rRNA methylase, respectively (8). The
present study was conducted to define the genetic basis of
multidrug resistance in A. baumannii by using a larger set of
isolates.
Approximately 20% of the MDR isolates were resistant to
carbapenems. We observed a clear correlation between the
presence of the OXA-23 gene and high-level carbapenem re-
sistance (Table 3). Indeed, transfer of blaOXA-23 to a suscep-
tible strain led to an 8- to 96-fold increase in carbapenem
MICs. This is in contrast to the other reports of carbapenem-
resistant A. baumannii outbreak investigations in the United
States, where carbapenem resistance was attributed to the pro-
duction of the OXA-40 carbapenemase or reduced expression
of outer membrane proteins in the absence of carbapenemase
activities (21, 28). Production of OXA-23 is the most fre-
quently encountered mechanism of carbapenem resistance in
A. baumannii worldwide (26). The degree of resistance in our
isolates was likely accentuated by the presence of strong pro-
moter sequences provided by ISAba1, leading to overproduc-
tion of the enzyme, as has been demonstrated with European
strains (7). Of note, the origin of blaOXA-23 was recently iden-
TABLE 4. MICs of amikacin in the presence or absence of armA
armA status
(no. of isolates)
No. of isolates with MICs (g/ml) of:
256 256 128 64 48 32 24 16 12 8 6 4 2 1
Positive (17) 17
Negative (32) 1 1 2 3 5 9 4 4 3
TABLE 3. MICs of imipenem in the presence or absence
of blaOXA-23
blaOXA-23 status
(no. of isolates)
No. of isolates with a MIC (g/ml) of:
32 32 24 16 8 6 4 3 2 1.5 1 0.75 0.5 0.38
Positive (8) 8
Negative (41) 1 3 1 1 10 9 4 5 5 2
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tified as the chromosome of Acinetobacter radioresistens, a
commensal species of the human skin (27). Taking this to-
gether with the fact that ISAba1 is commonly found in various
Acinetobacter spp. (30), we may speculate that mobilization of
blaOXA-23 from A. radioresistens to A. baumannii occurs con-
currently under selective pressure from carbapenems in differ-
ent geographic areas. The diversity observed in the structures
of transposons carrying ISAba1 and blaOXA-23 in the United
States and Europe supports this hypothesis. The likelihood
that high-level carbapenem resistance may be acquired by A.
baumannii through transposon-mediated gene transfer from a
commensal organism underscores the importance of continued
efforts to limit carbapenem use in order to retain susceptibility
to these agents.
Resistance to amikacin was seen in nearly 40% of the study
isolates. Most of the resistant isolates were highly resistant
(MIC, 256 g/ml), and this resistance coincided with the
presence of the 16S rRNA methylase gene armA (Table 4).
Among the series of acquired 16S rRNA methylases, ArmA
appears to be the most common enzyme worldwide to date.
Although armA was initially identified in 2002 (12), it has been
shown that it was present in clinical isolates as early as 1997
(19). armA has been found mostly in Enterobacteriaceae, but its
presence has been documented in A. baumannii as well, mostly
in East Asia (20, 38). It is somewhat puzzling that we are
observing an increasing number of A. baumannii isolates that
produce ArmA, while the overall systemic use of aminoglyco-
sides has decreased at our facility in the past several years
(data not shown). One possibility is the presence of collateral
selective pressure from other resistance genes that are located
near armA. armA has been shown to be borne on an IS26-
based composite transposon in E. coli, which likely plays a role
in its mobilization (14). However, the only resistance genes
contained in this transposon were ant(3[dprime])-9, sul1, and
dfrXII, which confer resistance to streptomycin, sulfonamides,
and trimethoprim, respectively. Preliminary sequencing of the
genetic environment of our isolates revealed an identical struc-
ture at least in proximity to armA (8). We are currently con-
ducting further investigations of the genetic environment of
armA in order to clarify the mode of its mobilization in A.
baumannii.
In contrast to the strong association observed between the
presence of armA and high-level aminoglycoside resistance,
including amikacin resistance, the roles of the amikacin-mod-
ifying enzyme genes aac(6)-Ib and aph(3)-VIa in amikacin
resistance were less clear. One possible explanation, at least for
aac(6)-Ib, is that the gene is typically carried on integrons as
a gene cassette lacking its own promoters, and thus its expres-
sion may be suboptimal depending on its distance from the
common promoter sequences located at the 5 conserved seg-
ment of the integrons (6).
All of the isolates were resistant or intermediate to cipro-
floxacin. Resistance was associated with the typical substitu-
tions in the QRDRs of DNA gyrase and DNA topoisomerase
IV in all ciprofloxacin-resistant pulsotypes (34, 35). On the
other hand, no plasmid-mediated quinolone resistance genes
were detected in any of the isolates. These findings suggest that
resistance to fluoroquinolone in MDR A. baumannii depends
on target modification conferred by substitutions in the
QRDRs. Given the very high rate of resistance, however, this
class is unlikely to have any clinical role in the treatment of
MDR A. baumannii at our medical center.
FIG. 2. Schematic representation of the genetic environments of blaOXA-23 from the United States, France, and Turkey. (A) Strain AB017
(investigated in the present study); (B) strain AB13 (7); (C) strain AcKOU1 (GenBank accession no. EF120622). The boundaries of Tn2006 and
Tn2008 are indicated, along with the target site duplications (underlined). The 7-bp difference in the site of insertion of ISAba1 for strain AB13
is double underlined. Target site duplication was not identified within the available sequence for strain AcKOU1.
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More than half of the MDR isolates in the study belonged to
the same clonal type, i.e., pulsotype A, as evidenced by PFGE
(Table 2). Indeed, seven of eight isolates that were resistant to
six classes of antimicrobials belonged to this pulsotype and
carried both blaOXA-23 and armA. However, blaOXA-23 and
armA were also detected in different pulsotypes, indicating that
these genes are likely disseminating among A. baumannii
strains by means of horizontal transfer as well as clonal spread.
In conclusion, we have described the genetic basis of
resistance in MDR A. baumannii at a tertiary medical center
in Pennsylvania. Multidrug resistance was conferred pre-
dominantly by the production of OXA-23 carbapenemase,
ArmA 16S rRNA methylase, and resistance substitutions in
the QRDRs of DNA gyrase and DNA topoisomerase IV. As
the use of salvage agents such as colistin and tigecycline to
treat infections caused by these MDR organisms increases,
close monitoring of susceptibility to these agents is also
warranted.
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